ReShape Lifesciences Inc.

HIND

Explore Our Financial Data > Companies > ReShape Lifesciences Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
HIND
CIK0001427570
SIC2834
SectorManufacturing
Industry CategoryMedical Equipment
Industry GroupSurgical, Medical, And Dental Instruments And Supplies

Contact

Address1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
Website reshapelifesciences.com
Phone949-429-6680
CEOPaul F. Hickey
Employees50

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$6.45 million
Pre-Tax Income$-4.47 million
Net Income$-4.50 million
Net Income to Common$-4.50 million
EPS$-3.85
View All
Balance Sheet
Cash$4.12 million
Assets$9.03 million
Liabilities$3.20 million
Common Equity$5.83 million
Liabilities & Equity$9.03 million
View All
Cash Flow Statement
Net Income$-4.50 million
Cash From Operating Activities$-7.61 million
Cash From Investing ActivitiesN/A
Cash From Financing Activities$10.70 million
Change in Cash$3.07 million
View All
Calculations
NOPAT$-5.90 million
EBITDA$-4.46 million
Price to EarningsN/A
Price to Book$0.70
ROE-101.49%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Vyome Holdings Acquires MIT AI Spinout Oculo Health

CAMBRIDGE, Mass., September 29, 2025--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology ("MIT"). Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo’s assets to develop an AI psychiatrist trained on data from bot

Article Link

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

CAMBRIDGE, Mass., September 17, 2025--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1).

Article Link

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

CAMBRIDGE, Mass., September 09, 2025--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development.

Article Link

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

CAMBRIDGE, Mass., September 04, 2025--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced the interim results from its investigator-initiated Phase 2 PoC study of VT-1953 topical gel in patients with malignant fungating wounds ("MFW"). The interim results were first presented at the recent annual meeting of the American Association for Cancer Research. Vyome Co-founder Dr. Shiladitya Sengupta will host a live video conference on Monday, September 8,

Article Link

Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio

CAMBRIDGE, Mass. & PUNE, India, August 21, 2025--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, and Embryyo Technologies today announced the signing of an MoU (Memorandum of Understanding) to jointly pursue the global AI-enabled medical device market. This partnership will combine Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to potentially productize and commercialize smart medical devices that can transfor

Article Link